An assessment of methods to combine published survival curves

被引:57
作者
Earle, CC
Wells, GA
机构
[1] Univ Ottawa, Ottawa, ON, Canada
[2] Ottawa Reg Canc Ctr, Ottawa, ON K1Y 4K7, Canada
关键词
survival analysis; meta-analysis; life tables; proportional hazards models;
D O I
10.1177/0272989X0002000113
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Purpose. To assess the accuracies of different techniques for combining published survival curves, for use in disease modeling applications. Methods. Five methods were identified: 1) iterative generalized least-squares (IGLS), 2) meta-analysis of failure-time data with adjustment for covariates (MFD), 3) nonlinear regression (NLR), 4) log relative risk (LRR), and 5) weighted LRR (w-LRR). Each method was used to combine the survival curves from eight single-arm Phase II trials of chemotherapy in 918 patients with advanced non-small-cell lung cancer (NSCLC). The resulting summary curves were compared with the curve calculated from the corresponding individual patient data (IPD). Results. All methods were able to produce accurate summary survival curves statistically similar to the IPD-derived curve. Maximum discrepancies ranged from 1.8% to 4.7%. MFD appeared to be the most accurate when censoring information was complete. Characteristics of the component trials that adversely affected the accuracies of the different techniques were 1) a high proportion of censored observations (MFD); 2) variability in the length of follow-up (IGLS, NLR, LRR, w-LRR); and 3) the heterogeneity of the treatment results (NLR, w-LRR). Conclusions. All methods were able to accurately reproduce summary survival curves from the published literature. The best method depends on characteristics of the data and the purpose of the analysis.
引用
收藏
页码:104 / 111
页数:8
相关论文
共 43 条
[1]
ABE O, 1992, LANCET, V339, P71
[2]
A PITFALL IN THE META-ANALYSIS OF HAZARD RATIOS [J].
ABEL, UR ;
EDLER, L .
CONTROLLED CLINICAL TRIALS, 1988, 9 (02) :149-151
[3]
ALBERTI W, 1995, BRIT MED J, V311, P899
[4]
[Anonymous], 1998, Practical nonparametric statistics
[5]
A CONVENIENT APPROXIMATION OF LIFE EXPECTANCY (THE DEALE) .2. USE IN MEDICAL DECISION-MAKING [J].
BECK, JR ;
PAUKER, SG ;
GOTTLIEB, JE ;
KLEIN, K ;
KASSIRER, JP .
AMERICAN JOURNAL OF MEDICINE, 1982, 73 (06) :889-897
[6]
A COMPARISON OF STATISTICAL-METHODS FOR COMBINING EVENT RATES FROM CLINICAL-TRIALS [J].
BERLIN, JA ;
LAIRD, NM ;
SACKS, HS ;
CHALMERS, TC .
STATISTICS IN MEDICINE, 1989, 8 (02) :141-151
[7]
BUYSE M, 1988, EUR J CANC CLIN ONCO, V25, P1901
[8]
CISPLATIN CYCLOPHOSPHAMIDE MITOMYCIN COMBINATION CHEMOTHERAPY WITH SUPPORTIVE CARE VERSUS SUPPORTIVE CARE ALONE FOR TREATMENT OF METASTATIC NON-SMALL-CELL LUNG-CANCER [J].
CARTEI, G ;
CARTEI, F ;
CANTONE, A ;
CAUSARANO, D ;
GENCO, G ;
TOBALDIN, A ;
INTERLANDI, G ;
GIRALDI, T .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (10) :794-800
[9]
CLARKE M, 1995, CONTROL CLIN TRIALS, V16, pS67
[10]
Clarke M J, 1995, J Eval Clin Pract, V1, P119, DOI 10.1111/j.1365-2753.1995.tb00017.x